| Patient | Liliʻuokalani |
|---|---|
| Date of birth | 1947-09-02 |
| Identifiers | MRN HR-ET024-SYN; SSN (made up) 000-24-3086 |
| Document date | 2026-04-20 |
| Author | Kealani Morrison-Takeda, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week review: rhythm monitor result and anticoagulation. [S]
Liliʻuokalani returns five weeks after the stroke, with a member of her ʻohana. The 30-day monitor recorded six episodes of atrial fibrillation, the longest 3 hours 10 minutes, about 3% of the time, none of which she felt. She finished 21 days of aspirin and clopidogrel two weeks ago and now takes clopidogrel alone, with no bleeding. Her home blood pressure averaged 138/82 in the week after the stroke, so losartan 25 mg was started a week after the event; her home average is now 126/76. The potassium and creatinine check two weeks after starting losartan did not happen: the member of her household who drives her was away, and she did not want to trouble anyone. She has had no new neurological symptoms and plays the piano every morning. She has begun lomilomi with a practitioner at Ke Ola Mamo, who was told about her blood thinners. [S]
| Element | Detail |
|---|---|
| Rhythm monitor | Paroxysmal atrial fibrillation: six episodes, longest 3 hours 10 minutes, burden about 3%; no symptoms |
| Antiplatelets | 21 days of aspirin and clopidogrel completed; clopidogrel alone since |
| Home blood pressure | Average 126/76 mmHg on losartan 25 mg |
| Missed test | Potassium and creatinine two weeks after losartan not done; no ride |
| Function | Plays the piano daily; no new symptoms |
| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No new weakness, numbness, speech, vision or balance problem |
| Cardiovascular | Negative | No palpitations, breathlessness or fainting |
| Hematologic | Negative | No bruising, bleeding gums, black stools or blood in the urine |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency department | One tablet daily for 21 days | Oral route | 2026-03-16 to 2026-04-06 | completed | S |
| Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency department | One tablet daily | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Apixaban 5 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2026-04-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 160 | cm | S |
| 2026-04-20 | Body weight | 57.8 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 74 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.6 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 12.7 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | Cholesterol [Mass/volume] in Serum or Plasma | 138 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 64 | mg/dL | Goal below 70 mg/dL after ischemic stroke | Normal | S |
| 2026-04-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-04-20 | Triglyceride [Mass/volume] in Serum or Plasma | 92 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 130/78, pulse 74 and regular; weight 57.8 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Speech fluent; no drift; normal fine finger movements; normal gait |
| Skin | No bruising |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0 | resolved | provisional | G45.9 | S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms. |
| Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a stroke | active | confirmed | I63.412 | S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D. |
| Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intake | active | confirmed | I10 | S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources. |
| Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2 | active | confirmed | I48.0 | S — Synthetic finding on prolonged rhythm monitoring at five weeks. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 130/78 mmHg; home average 126/76; 57.8 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Deferred | The check due two weeks after losartan was started was missed: the member of her household who drives her was away, and she did not ask anyone else. Today, four weeks after the start, potassium is 4.5 mmol/L and creatinine 0.86 mg/dL (eGFR 69), both normal, so no harm resulted. Corrective action: tests drawn at clinic visits, or at home by the clinic's nurse |
| Imaging | ECG and prolonged rhythm monitoring for atrial fibrillation | ECG at baseline; at least 30 days of monitoring within six months of the event | Completed today | 30 days of monitoring: paroxysmal atrial fibrillation, six episodes, burden about 3% |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | 21 days of dual antiplatelets completed; clopidogrel stopped today; apixaban 5 mg twice daily started |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Before apixaban: hemoglobin 12.7 g/dL, platelets 228, creatinine 0.86 mg/dL (creatinine clearance about 49 mL/min), ALT 22 U/L |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Completed today | Five weeks on atorvastatin 40 mg: LDL 64 mg/dL, total cholesterol 138, HDL 56, triglycerides 92 |
| Imaging | Carotid and intracranial vessel imaging | At the event; follow-up only for treated or moderate or greater stenosis | Not indicated | Carotid plaque under 50%; no follow-up imaging needed |
| Examination | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | With any change; modified Rankin Scale at 90 days | Completed today | No new symptoms; examination normal |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Up to date | MoCA 26 at the stroke clinic; repeat within the first year |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Up to date | PHQ-2 1 at the stroke clinic; PHQ-9 at three months |
| Examination | Falls risk | Every visit | Completed today | No falls; falls plan reviewed before starting an anticoagulant |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Lomilomi at Ke Ola Mamo by her choice, with the practitioner told about her blood thinners; the decision on apixaban was hers, with her ʻohana present |
Goal progress:
Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke (2024); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026)
Follow-up: Three-month review in eight weeks. Call for bleeding that will not stop, black stools or any fall with a blow to the head; call 911 for any BE FAST sign. Next scheduled visit 2026-06-15: three-month review after the stroke: function, mood, blood pressure, apixaban safety and falls. [S]